Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: SPSEIFERT who wrote (2004)	7/15/1998 10:20:00 AM
From: Caveat Emptor	Respond to of 2553

Info Sent to SEC/NASDR - Spinning Allegations intelico.com I have been involved with researching the venture funding of this company for some time. The focus is on compensation practices of the Investment Company/Venture Funding entitiy (Paine Webber et al), and certain executives of the companies they finance. Recently at the SEC Enforcement Division, a focus has been on this type of compensation, or "Spinning" as it is called. My fact patttern, developed via public document research has developed a fact pattern which I believe shows "questionable" patterns of compensation. This board, as well as others is dedicated to investors sharing information about their concerns about a stock. This shows major insider shifting of stock ownership as recently as 11/97. This type of shift, involving the Genzyme Development Partnership (as General Partners) I believe could effect the long and short term. The relationships between COmpany Officers/Directors and Insiders bothers me. Please review the posted material, and I will continue to monitor this board for questions and further information. CAVEAT EMPTOR

To: SPSEIFERT who wrote (2004)	7/15/1998 10:39:00 AM
From: Caveat Emptor	Respond to of 2553

Look at the 13D of Bioroyaltiesl/Pharmaceutical Partners The major shift in insider position of Genzyme (Genzl) is documented in the recently filed 13D outlined below. Along with this 13 D FIling, you can also research this partnerships long term relationship with Genzyme Development Partners, LP. Since 1989. Because of the Shared common management, and "intertwined" General Partnership Interests involved here with Executives of the company, I have concerns. How can this majority ownership effect the stock price? We need to discuss.. what are your thoughts. Because of my concerns, I haver forwarded this information to the SEC and NASDR for review in their "Spinning" probe. I'm just looking for discussion and possible answers from both the SEC and other investors. For the 13D sec.gov Click into Edgar At the prompt, type BIOROYALTIES Review 13d of Paine Webbber R+D Partners 11 Review the 10K for outline of PW Interest in Genzyme CAVEAT EMPTOR

To: SPSEIFERT who wrote (2004)	7/15/1998 10:46:00 AM
From: Caveat Emptor	Respond to of 2553

Furher Information - Insiders of Genzyme I have identified other major institutional stockholders of Genzyme FYI This is a hedge fund/venture funding partnership based in CT. Although they are not identified on Genzyme Filings as being a 5%+ owner of stock, their web site identifies them as a major stockholder, as well as being involved as an investor in Genzyme since 1989. Research has found that this partnership (Oak Investment Partners) has been involved with Paine Webber R+D Partners 11 for many years. Many of their portfolio companies are the same as Paine Webber R+D 11. General Partner - Ginger More oakinv.com CAVEAT EMPTOR